Brooklyn ImmunoTherapeutics, Inc. (BTX) Report Analysis
Corporate Events
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Value Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Value Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell Small Cap Comp Value Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell Small Cap Comp Value Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Value Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Value Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell Small Cap Comp Growth Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell Small Cap Comp Growth Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 3000 Growth Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 3000 Growth Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 3000 Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 3000 Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 3000 Value Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 3000 Value Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell Small Cap Completeness Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell Small Cap Completeness Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Growth Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Growth Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Dynamic Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2000 Dynamic Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Growth Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from Russell 2500 Growth Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to Russell Microcap Value Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to Russell Microcap Value Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to Russell Microcap Growth Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to Russell Microcap Growth Index
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to Russell Microcap Index
2022-06-24 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to Russell Microcap Index
Brooklyn ImmunoTherapeutics, Receives Non-Compliance Letter from Nasdaq
2022-06-17 21:22:00
On June 17, 2022, Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the Company"), received a notice (the Notice") from the Nasdaq Stock Market LLC (Nasdaq"), stating that the Company's common stock, par value $0.005 per share (the common stock"), fails to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company's common stock will be subject to delisting from Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 14, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to December 14, 2022. If the Company is unable to regain compliance by December 14, 2022, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the minimum bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180 calendar day period, then Nasdaq will notify the Company of its determination to delist the common Stocks, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel. The Company will monitor the closing bid price of its common stock and is considering its options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
Brooklyn ImmunoTherapeutics, Inc. Announces Executive Changes
2022-06-07 20:45:00
Brooklyn ImmunoTherapeutics, Inc. announced that On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board. The Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby. Each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer will serve as a member of the Board until the Annual Meeting and until his successor is duly elected or appointed and qualified or his earlier death, resignation or removal. The Board appointed each of Mr. Wexler and Mr. Singer to serve as a member of the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee . Dr. Angel, 41 years old, has served as the Company’s interim President and Chief Executive Officer since May 26, 2022. Prior to that, Dr. Angel co-founded Factor Bioscience Inc. and served as its President, Chief Executive Officer and Chairman of its Board of Directors from 2011 to 2022. In 2020, Dr. Angel co-founded Exacis Biotherapeutics Inc. (“ Exacis”), an immuno-oncology company, for which he serves as the Scientific Advisory Board Chair. Dr. Angel previously served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis Biotherapeutics Inc., and as the Chief Science Officer, Secretary and as a director of Novellus, Inc. patented non-immunogenic mRNA, from 2014 until the sale of Novellus to the Company in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003. Dr. Fiore, 52 years old, has served as a director and as the President and Chief Executive Officer of Exacis since June 2020. Dr. Fiore co-founded Sollis Therapeutics where he served as President, Chief Executive Officer and Director from 2017 to 2019 and as Vice President and Chief Medical Officer from 2019 to 2020. Prior to Sollis, Dr. Fiore provided senior medical support as a consultant and acting Chief Medical Officer for various early-stage biotechnology companies through the following private healthcare consulting firms he founded, Fiore Healthcare Advisors, SSI Strategy and GJFMD Consulting. Dr. Fiore was also the Chief Medical Officer of The Medicines Company held leadership roles at Merck & Co., Inc. and Abbott Laboratories and was a management consultant at McKinsey and Company. Dr. Fiore has served as a member of the Business Advisory Board for The Advanced Group of Companies since 2017. Dr. Fiore completed his Internal Medicine internship and residency at Harvard Medical School and received his MD degree from New York Medical College. Mr. Wexler, 63 years old, has worked on over 150 individual projects, serving in various capacities including as Chairman, Chief Executive Officer, Chief Restructuring Officer and other designated roles of senior responsibility. Mr. Wexler has served as the Managing Member of WEXLER Consulting LLC, since 2012. From 2012 to 2019, he served in various roles, including as Chairman of the Board, interim Chief Executive Officer, Chief Executive Officer and sole director and stockholder representative of Upstate New York Power Products, Inc., a holding company that owned and operated power plants throughout upstate New York. From 2012 to 2013, Mr. Wexler served as Chief Restructuring Officer of VMR Electronics, LLC, a manufacturer of cable assembly products for the electronics interconnect industry. Prior to that, he served as a Managing Director and national finance practice lead at BBK Ltd., a turn-around advisory firm, from 2006 to 2011. Mr. Wexler served as group Managing Director of corporate restructuring at Huron Consulting Group, LLC from 2002 to 2005. Previously, he was a Managing Director at Berenson Minella & Co., a boutique investment-banking firm, from 2000 to 2002. Between 1986 and 2000 he served as a Senior Director at BNP Paribas, where he established and led Paribas Properties, Inc., a real estate investment arm of the bank, and also where he was a lead officer of the then newly created U.S. asset workout group. Mr. Wexler started his professional career in 1981 in commercial lease brokerage, asset management and investment sales at Jones Lang Wootton (now Jones Lang LaSalle) where he worked until 1986. He earned a B.A. in Political Science from Johns Hopkins University. Mr. Singer, 42 years old, has over 20 years of experience in finance and investments. Mr. Singer is the Founder of Purchase Capital LLC, an investment firm that serves as his family office and sponsor to leading institutional investors and third-party family offices. Since Mr. Singer became Managing Member in 2013, Purchase Capital has provided patient capital for private and public companies that have significant potential for long-term value creation. From August 2020 through May 2022, Mr. Singer served as the Chairman and Chief Executive Officer of OTR Acquisitions Corp., a blank check company formed for the purposes of engaging in business combinations. From March 2021 through April 2021, Mr. Singer served on the Board and as a member of its audit committee. He is also the Founder & Executive Chairman of United Parks, the Chairman of the board of directors of Only What Need, Inc., the Executive Chairman of IntegriCo Composites and a Trustee of the Pérez Art Museum Miami. From 2007 to 2013, Mr. Singer was the Co-Founder & Co-Managing Member of Standard General, a Securities and Exchange Commission (the “SEC” registered investment advisor which managed over $1 billion of assets during his tenure. Prior to that, he was a Co-Founder of Cyrus Capital Partners, a Principal at Och-Ziff Capital Management, and an Analyst in High Yield Trading and in the Principal Investment Area at Goldman Sachs & Co. Mr. Singer also served as a director for, and was on the audit committee of, Aquila, Inc. from 2006 to 2008. He graduated summa cum laude with a B.S. in Economics from the Wharton School and a B.A.S. in Electrical Engineering from the School of Engineering and Applied Science at the University of Pennsylvania.
Brooklyn ImmunoTherapeutics, Inc. Announces Board Changes
2022-06-07 11:30:00
Brooklyn ImmunoTherapeutics Inc. announced the appointments to the Board, effective June 5, 2022. Matt Angel, Ph.D., Interim Chief Executive Officer (“CEO”) of Brooklyn and Co-Founder, Chairman, President and CEO of Factor Bioscience Inc. Gregory Fiore, Co-Founder, President, and CEO of Exacis Biotherapeutics. Nicholas Singer, Founder and Managing Member of Purchase Capital. Bill Wexler, Chairman and CEO of Homer City Holdings, LLC. Erich Mohr, Dennis Langer, Heather Redman, and Erin Enright departed the Board effective June 5, 2022. Matt Angel, Ph.D.: Dr. Angel is an experienced biotechnology entrepreneur and executive, having led Factor Bioscience Inc. as CEO since its founding in 2011. Dr. Angel is Co-Founder of the immuno-oncology company, Exacis Biotherapeutics, where he serves as Scientific Advisory Board Chair, and the cell therapy company, Novellus Therapeutics, which was acquired by Brooklyn in 2021. Dr. Angel has deep experience in cell therapy product development, intellectual property protection and licensing, contract negotiation, including collaboration and licensing agreements, and has raised more than $150 million through grants, equity financings, and M&A. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his Ph.D. from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA. Gregory Fiore, MD: Dr. Fiore is a co-founder and is the President and Chief Executive Officer of Exacis Biotherapeutics. He is a pharmaceutical/biotechnology executive and entrepreneur and is a co-founder and former CEO of Sollis Therapeutics, where during his tenure as CEO he raised $50 million in funding from State grants as well as strategic venture investors. He oversaw the regulatory strategy development and initiation of pivotal clinical trials for the Company’s lead compound. Before this he provided C-level medical support as consultant and acting Chief Medical Officer for several early-stage biotechnology companies through two consultancies he founded. Dr. Fiore was the first CMO of The Medicines Company and held a variety of leadership roles at The Medicines Company, Merck and Abbott Laboratories after spending time as a management consultant at McKinsey and Company. Dr. Fiore completed Internal Medicine internship and residency as well as received clinical Pulmonary /Critical Care training at Harvard Medical School and received his MD degree from New York Medical College. Nicholas Singer: Nicholas J. Singer has over 20 years of experience in finance and investments and is the Founder and Managing Member of Purchase Capital. He is also the Founder and Executive Chairman of United Parks, the Executive Chairman of IntegriCo Composites, the Chairman of Only What You Need (OWYN), and a Trustee of the Pérez Art Museum Miami. From 2007 to 2013, Mr. Singer was the Co-Founder & Co-Managing Member of Standard General, an SEC registered investment advisor which managed over $1 billion of assets during his tenure. Prior to that, he was a Founding Partner of Cyrus Capital Partners, a Principal at Och-Ziff Capital Management, and an Analyst in High Yield Trading and in the Principal Investment Area at Goldman Sachs & Co. He graduated summa cum laude with a B.S. in Economics from the Wharton School and a B.A.S. in Electrical Engineering from the School of Engineering and Applied Science at the University of Pennsylvania. Bill Wexler: Mr. Wexler has worked on over 150 individual projects, serving in various capacities including: Chairman; Chief Executive Officer; Chief Restructuring Officer and other designated roles of senior responsibility. Since 2017, he has served as Chairman of the Board and Chief Executive officer of Homer City Holdings, LLC which owns and operates a multiple unit merchant power plant which is located in western Pennsylvania. From July 2012 to December 2019, he served in various roles, including as Chairman of the Board, Chief Executive Officer and sole Director and shareholder representative of Upstate New York Power Products Inc. which owned and operated merchant power plants throughout upstate New York. From January 2012 to April 2013, Mr. Wexler served as Chief Restructuring Officer of VMR Electronics, LLC, a manufacturer of cable assembly products for the electronics interconnect industry. Between 2006 and 2011, he served as a managing director and national finance practice lead at BBK Ltd., a turn-around advisory firm. From 2002 to 2005, he served as Group Managing Director of Corporate Restructuring at Huron Consulting Group, LLC. From 2000 to 2002, he was a Managing Director at Berenson Minella & Co., a boutique investment-banking firm. Between 1986 and 2000 he served as a Senior Director at BNP Paribas, where he established and led Paribas Properties Inc., a real estate investment arm of the bank. In addition, he was a Senior Officer in the bank’s North American asset workout group. Mr. Wexler began his career in 1981 in commercial lease brokerage, asset management and investment sales at Jones Lang Wootton. He earned a B.A. in Political Science from Johns Hopkins University.
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from S&P Global BMI Index
2022-06-06 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from S&P Global BMI Index
Brooklyn Immunotherapeutics Announces Executive Management Changes
2022-05-31 11:30:00
Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim ChiefExecutive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief Financial Officer.
Brooklyn Immunotherapeutics, Inc. Announces Appointment of Andrew Jackson as Chief Financial Officer
2022-05-31 11:30:00
Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Andrew Jackson as Chief Financial Officer.
Brooklyn Immunotherapeutics Announces Executive Changes
2022-05-31 11:30:00
Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. Dr. Angel is an experienced biotechnology entrepreneur and executive, having led Factor Bioscience Inc. as CEO since its founding in 2011. Dr. Angel is Co-Founder of the immuno-oncology company, Exacis Biotherapeutics, where he serves as Scientific Advisory Board Chair, and the cell therapy company, Novellus Therapeutics, which was acquired by Brooklyn in 2021. Dr. Angel has deep experience in cell therapy product development, intellectual property protection and licensing, contract negotiation, including collaboration and licensing agreements, and has raised more than $150 million through grants, equity financings, and M&A. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. Dr. Angel received his Ph.D. from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA.Mr. Jackson joins the Company from Ra Medical Systems, a medical device company focused on vascular diseases where he served as its Chief Financial Officer and Secretary and for a period, its Interim Chief Executive Officer. Mr. Jackson has held several senior financial positions, including Chief Financial Officer, at AltheaDx, Inc, a commercial stage molecular diagnostics company specializing in precision medicine and Celladon Corporation, a publicly-traded, clinical stage gene therapy company, as well as senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota. Mr. Jackson is also a certified public accountant (inactive).
Brooklyn ImmunoTherapeutics, Inc. Announces Board Retirements
2022-05-31 11:30:00
Brooklyn ImmunoTherapeutics, Inc. announced on May 24, 2022, Heather Redman, Erich Mohr and Erin Enright delivered notices to the Board of their respective decisions not to stand for reelection at the Company’s 2022 annual meeting of stockholders, currently scheduled for June 7, 2022. On May 26, 2022, Dennis Langer similarly delivered notice to the Board of his decision not to stand for reelection at the Annual Meeting. Ms. Redman, Ms. Enright, Dr. Mohr and Dr. Langer currently remain directors, and none of them has yet provided a specific date on which his or her Board service will cease, as the current Board actively interviews and seeks new candidates with appropriate qualifications to serve on the Board. The decisions of the foregoing directors not to stand for reelection were not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
2022-05-27 00:00:00
Brooklyn ImmunoTherapeutics, Inc. announced that it received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Quarterly Report”), Brooklyn is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice has no immediate effect on the listing of Brooklyn’s shares on Nasdaq. The Company previously reported the circumstances with respect to the late filing of the Quarterly Report in a Notification of Late Filing on Form 12b-25, filed with the Securities and Exchange Commission on May 17, 2022. The Company's management is working diligently to complete the Quarterly Report, and intends to file it as soon as practicable. Under Nasdaq rules, Brooklyn has 60 calendar days, or until July 25, 2022, to either file the Quarterly Report or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule (the “Compliance Plan”). If Brooklyn does not file the Quarterly Report but submits a Compliance Plan, and Nasdaq accepts the Compliance Plan, then Nasdaq may grant Brooklyn up to 180 days from the prescribed due date, or until November 18, 2022, for filing the Quarterly Report to regain compliance. If Nasdaq does not accept Brooklyn’s Compliance Plan, then Brooklyn will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.
Brooklyn ImmunoTherapeutics, Inc. announced delayed 10-Q filing
2022-05-17 00:00:00
On 05/17/2022, Brooklyn ImmunoTherapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Brooklyn ImmunoTherapeutics, Inc. has closed its Shelf Registration dated April 29, 2022 in the amount of $15.359998 million.
2022-05-11 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has closed its Shelf Registration dated April 29, 2022 in the amount of $15.359998 million. Security Name: Common Stock Securities Offered: 13,714,284
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $15.359998 million.
2022-04-29 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $15.359998 million. Security Name: Common Stock Securities Offered: 13,714,284
Brooklyn ImmunoTherapeutics, Inc. - Shareholder/Analyst Call
2022-04-26 21:01:00
Annual Meeting of Stockholders
Brooklyn ImmunoTherapeutics, Inc., Annual General Meeting, Jun 07, 2022
2022-04-26 21:01:00
Brooklyn ImmunoTherapeutics, Inc., Annual General Meeting, Jun 07, 2022, at 11:00 US Eastern Standard Time. Agenda: To elect as directors the six nominees for a term of office expiring at the 2023 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified; to consider the compensation of named executive officers; to consider the frequency of the non-binding advisory resolution regarding the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the 2022 fiscal year; and to consider any other business that is properly presented at the meeting and any adjournment or postponement thereof.
Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
2022-04-21 11:30:00
Brooklyn ImmunoTherapeutics, Inc. announced the establishment of a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, California to support translational R&D for cell therapies and genetic medicines.
Brooklyn ImmunoTherapeutics, Inc. to Report Q4, 2021 Results on Apr 15, 2022
2022-04-15 21:18:00
Brooklyn ImmunoTherapeutics, Inc. announced that they will report Q4, 2021 results on Apr 15, 2022
Brooklyn ImmunoTherapeutics, Inc. announced delayed annual 10-K filing
2022-04-01 00:00:00
On 04/01/2022, Brooklyn ImmunoTherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Brooklyn Immunotherapeutics, Inc. Announces That Luba Greenwood Notified the Board of Directors of Her Intention to Resign as A Director Effective as of January 1, 2022
2021-12-21 21:30:00
Brooklyn ImmunoTherapeutics, Inc. announced that Luba Greenwood notified the board of directors of her intention to resign as a director effective as of January 1, 2022. Ms. Greenwood’s decision to resign was not the result of any disagreement with on any matter relating to operations, policies or practices.
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to NASDAQ Biotechnology Index
2021-12-20 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has been added to NASDAQ Biotechnology Index.
Brooklyn ImmunoTherapeutics, Inc. Presents at MedInvest Oncology Conference, Dec-09-2021 11:20 AM
2021-12-02 13:04:00
Brooklyn ImmunoTherapeutics, Inc. Presents at MedInvest Oncology Conference, Dec-09-2021 11:20 AM. Speakers: Howard J. Federoff, CEO, President & Director.
Brooklyn ImmunoTherapeutics, Inc. Presents at Benzinga Global SmallCAP Conference, Dec-08-2021 04:40 PM
2021-12-02 10:47:00
Brooklyn ImmunoTherapeutics, Inc. Presents at Benzinga Global SmallCAP Conference, Dec-08-2021 04:40 PM. Speakers: Howard J. Federoff, CEO, President & Director.
Brooklyn ImmunoTherapeutics, Inc. Appoints Susan McClatchey as Head of Quality
2021-11-29 13:00:00
Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Susan McClatchey as Vice President, Head of Quality. Ms. McClatchey joins Brooklyn from IQVIA, a San Diego-based cell and gene therapy translation center. Previously she has held key quality positions at ViaCyte, Cosmo Bioscience, the American Red Cross National Testing Laboratory, BioAgilytix (formerly MicroConstants), GenStar Therapeutics, and IDEC Pharmaceuticals. She holds a Bachelor of Science degree in Biology from the University of California, San Marcos and a professional certification in clinical trials management from the University of California San Diego Extension.
Brooklyn ImmunoTherapeutics, Inc. has closed its Shelf Registration dated November 18, 2021 in the amount of $48.492825 million.
2021-11-26 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has closed its Shelf Registration dated November 18, 2021 in the amount of $48.492825 million. Security Name: Common Stock Securities Offered: 6,281,454
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $45.352098 million.
2021-11-18 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $45.352098 million. Security Name: Common Stock Securities Offered: 6,281,454
Brooklyn ImmunoTherapeutics, Inc. has withdrawn its Shelf Registration dated August 13, 2021 in the amount of $73.74427 million.
2021-11-18 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has withdrawn its Shelf Registration dated August 13, 2021 in the amount of $73.74427 million. Security Name: Common Stock Securities Offered: 6,281,454
MedInvest, MedInvest Oncology Conference, Dec 07, 2021 through Dec 10, 2021
2021-11-12 14:00:00
MedInvest, MedInvest Oncology Conference, Dec 07, 2021 through Dec 10, 2021.
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to NASDAQ Composite Index
2021-10-26 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has been added to NASDAQ Composite Index.
Accretive Capital LLC, Benzinga Global SmallCAP Conference, Dec 08, 2021 through Dec 09, 2021
2021-10-14 14:12:00
Accretive Capital LLC, Benzinga Global SmallCAP Conference, Dec 08, 2021 through Dec 09, 2021.
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $43.487122 million.
2021-10-12 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $43.487122 million. Security Name: Common Stock Securities Offered: 5,116,132 Transaction Features: ESOP Related Offering
Brooklyn ImmunoTherapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021
2021-09-27 23:05:00
Brooklyn ImmunoTherapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States.
Brooklyn ImmunoTherapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021
2021-09-23 22:02:00
Brooklyn ImmunoTherapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 . Venue: New York, United States.
Marcum LLP Replaces Baker Tilly Us, LLP as Independent Registered Public Accounting Firm of Brooklyn ImmunoTherapeutics, Inc
2021-09-23 20:30:00
Brooklyn ImmunoTherapeutics, Inc. announced that on April 21, 2021, the audit committee dismissed Baker Tilly US, LLP, or Baker Tilly, as the company's independent registered public accounting firm. On September 20, 2021, the audit committee of the board of directors approved the appointment of Marcum LLP, or Marcum, as the company's new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal year ending December 31, 2021. Prior to the appointment of Marcum on September 20, 2021, the company had not appointed any firm to perform independent audit services for the fiscal year ending December 31, 2021.
Brooklyn ImmunoTherapeutics, Inc. Appoints Roger Sidhu as Chief Medical Officer
2021-09-22 14:07:00
Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma. Previously, he held key positions at Roivant Sciences, where he was Chief Medical Officer and Executive Vice President and Head of Research and Development, Cell Design Labs, where he served as Chief Medical Officer, and Amgen, where he served as Global Product General Manager, Translational Sciences.
Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) added to S&P Global BMI Index
2021-09-20 00:00:00
Brooklyn ImmunoTherapeutics, Inc.(NYSEAM:BTX) added to S&P Global BMI Index
Brooklyn ImmunoTherapeutics, Inc. - Special Call
2021-09-13 12:00:00
Brooklyn ImmunoTherapeutics, Inc. - Special Call
Brooklyn ImmunoTherapeutics, Inc. Approves Amendment to Its Certificate of Incorporation
2021-09-13 10:06:00
Brooklyn ImmunoTherapeutics, Inc. held its 2021 Annual Meeting of Stockholders on August 20, 2021. At the meeting the shareholders approved the ratification of the amendment to its certificate of incorporation to effect an increase in the number of authorized shares of common stock from 15,000,000 to 100,000,000.
Brooklyn ImmunoTherapeutics, Inc. - Special Call
2021-08-16 20:15:00
Brooklyn ImmunoTherapeutics, Inc. - Special Call
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $73.74427 million.
2021-08-13 00:00:00
Brooklyn ImmunoTherapeutics, Inc. has filed a Shelf Registration in the amount of $73.74427 million. Security Name: Common Stock Securities Offered: 6,281,454
Brooklyn ImmunoTherapeutics, Inc. Presents at SNN Network Summer Virtual Event 2021, Aug-18-2021 12:00 PM
2021-08-05 14:36:00
Brooklyn ImmunoTherapeutics, Inc. Presents at SNN Network Summer Virtual Event 2021, Aug-18-2021 12:00 PM. Speakers: Howard J. Federoff, CEO, President & Director.
Brooklyn ImmunoTherapeutics, Inc., Novellus Therapeutics Limited - M&A Call
2021-07-19 12:00:00
To discuss the transaction and future plans
Brooklyn ImmunoTherapeutics, Inc. (NYSEAM:BTX) completed the acquisition of Novellus Therapeutics Limited for approximately $100 million.
2021-07-16 00:00:00
Brooklyn ImmunoTherapeutics, Inc. (NYSEAM:BTX) (BTX) signed a non-binding letter of intent to acquire Novellus Therapeutics Limited for approximately $130 million on June 13, 2021. The consideration will be paid by a combination of $17.4 million in cash and $107.6 million in BTX common stock. The cash component of the transaction will be funded from $43 million of cash in BTX' balance sheet. The completion of the transaction is subject to several conditions, including, completion of mutually satisfactory due diligence, execution of the definitive agreement, and receipt of all required corporate and third-party approvals, regulatory and board approvals, along with other customary conditions. The transaction is expected to complete on or before July 15, 2021. Brooklyn ImmunoTherapeutics, Inc. entered into an acquisition agreement to acquire Novellus Therapeutics Limited on July 16, 2021. Brooklyn ImmunoTherapeutics, Inc. (NYSEAM:BTX) completed the acquisition of Novellus Therapeutics Limited for approximately $100 million on July 16, 2021. Brooklyn delivered consideration which consisted of $22.853 million cash net of $0.28 million cash and 7.02 million shares of common stock, consisting of 3.64 million of unrestricted shares and 3.38 million restricted shares valued at $6.53 per share. A total of 740,766 of the restricted and unrestricted shares issued as consideration have been placed in escrow for a period of up to 12 months in order to secure indemnification obligations to Brooklyn under the Acquisition Agreement. Andy McConnell of Philip Lee Solicitors acted as the legal advisor to Novellus Therapeutics. Back Bay Life Science Advisors acted as financial advisor to Novellus.
Brooklyn Immunotherapeutics, Inc. Announces Appointment of Jay Sial as Its Chief Administrative Officer, Effective July 15, 2021
2021-07-13 12:15:00
Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Jay Sial as its Chief Administrative Officer, effective July 15, 2021. Prior to joining Brooklyn, Mr. Sial served as Chief Financial Officer at Aspen Neurosciences, a privately-held emerging biotechnology company. Before that he served as Chief Financial Officer at multiple complex organizations, including University of California Irvine Health, Trinity Health/Loyola University Health System and University of Kentucky Healthcare. He also served in key financial and management roles at Thomas Jefferson University Hospital and FHP, Inc., a health maintenance organization (HMO) based in Fountain Valley, California.
SNN, Inc., SNN Network Summer Virtual Event 2021, Aug 17, 2021 through Aug 19, 2021
2021-07-11 10:50:00
SNN, Inc., SNN Network Summer Virtual Event 2021, Aug 17, 2021 through Aug 19, 2021.
Brooklyn ImmunoTherapeutics, Inc. Presents at Access to Giving Virtual Conference, Jul-15-2021 09:00 AM
2021-07-07 13:07:00
Brooklyn ImmunoTherapeutics, Inc. Presents at Access to Giving Virtual Conference, Jul-15-2021 09:00 AM. Venue: Raleigh, United States. Speakers: Howard J. Federoff, CEO, President & Director.
Brooklyn ImmunoTherapeutics, Inc. - Shareholder/Analyst Call
2021-07-01 21:17:00
Annual General Meeting
Brooklyn ImmunoTherapeutics, Inc., Annual General Meeting, Sep 03, 2021
2021-07-01 21:17:00
Brooklyn ImmunoTherapeutics, Inc., Annual General Meeting, Sep 03, 2021, at 09:00 US Eastern Standard Time. Agenda: To consider the election of five directors; to consider the ratification of charter amendment to increase authorized common stock; and to consider the approval of restated 2020 stock incentive plan.
Brooklyn ImmunoTherapeutics, Inc. Announces Ratification of Charter Amendment to Increase Authorized Common Stock
2021-07-01 21:17:00
Brooklyn ImmunoTherapeutics, Inc. announced that stockholders to ratify an earlier amendment to restated certificate of incorporation to increase the number of authorized shares of common stock from 15,000,000 shares to 100,000,000 shares, which refer to as the Share Increase Amendment. The Share Increase Amendment was submitted for stockholder approval at a special meeting of stockholders held on March 15, 2021, or the Special Meeting, and was intended to be effected by the filing of the Share Increase Amendment with the Delaware Secretary of State on March 25, 2021.
Fundamental Summary
Brooklyn ImmunoTherapeutics's financial reports for Q3 showed some underwhelming results. Their negative income, growth, and value factors indicate that the company is finding it increasingly difficult to produce impressive numbers. These troubling results make a strong case for underperformance and for anticipating a significant downside. Therefore, we assessed them with a rating of 56 and a UNDERPERFORM recommendation.
Brooklyn ImmunoTherapeutics reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 8.46 million compared to USD 21.46 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 1.22 a year ago. Diluted loss per share from continuing operations was USD 0.16 compared to USD 1.22 a year ago.
Business Description
Brooklyn ImmunoTherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics is based in Brooklyn, New York.
Sector Overview
Brooklyn ImmunoTherapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Brooklyn ImmunoTherapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Assets | 39.4 | -39.1% | 71 | |
| Liabilities | 26.4 | -10.7% | 37 | |
| Price to Book | 37.1 | 62.2% | 55 | |
| Cash & Equivalents | 24.4 | -51.4% | 39 | |
| Equity | 13.0 | -62.9% | 45 | |
| EBITDA | -20.4 | -22.0% | 49 |
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -1,186.7 | -443.3% | 92 | |
| Net Cashflow | 21.3 | -52.6% | 58 | |
| Capital Expenditure | -0.0 | -53.5% | 43 | |
| Free Cashflow | -0.5 | 2.4% | 72 |
* All values are TTM
The below chart reflects Brooklyn ImmunoTherapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Brooklyn ImmunoTherapeutics's peer average final assessment score stands on 62.0, Brooklyn ImmunoTherapeutics's score is 56.
- BTX
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Brooklyn ImmunoTherapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Brooklyn ImmunoTherapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.
5D MA
0.57
50D MA
0.81
200D MA
4.13
MACD
-0.08
RSI
1.92
STOCH
34.41
Balance Sheet Analysis
A few key balance sheet metrics in this report were discouraging. At filing, Brooklyn ImmunoTherapeutics's liabilities were 26.4, representing a -10.7% change from the previous period. Brooklyn ImmunoTherapeutics's liabilities changes appear mediocre compared to their peers. Contextually, they convey that management finds balancing asset growth, resource allocation, and liabilities challenging. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 37. Also, Brooklyn ImmunoTherapeutics did a poor job related to managing cash and cash equivalents this period, which stood at 24.4, representing a -51.4% change from the previous filing. Their anemic growth in cash and cash equivalents, specifically in contrast to their industry peers' performance, should hurt their stock price. Its cash and cash equivalents movement, therefore, received a grade of 39. However, one encouraging metric, Assets, stood out. Brooklyn ImmunoTherapeutics's management was effective in managing the value of the assets on their balance sheet, which now sits at 39.4 and represents a -39.1% change from the previous report. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its asset component earned a score of 71. Consequently, their balance sheet earned a rank of 49.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 39.4 | -39.1% | 71 |
| Liabilities | 26.4 | -10.7% | 37 |
| Price to Book | 37.1 | 62.2% | 55 |
| Cash & Equivalents | 24.4 | -51.4% | 39 |
| Equity | 13.0 | -62.9% | 45 |
The below chart describes Brooklyn ImmunoTherapeutics's performance as reflected on its balance sheet with respect to its peers. While Brooklyn ImmunoTherapeutics received a balance sheet score of 49, the average of its peers stands on 67.0.
- BTX
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 0 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 2 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 5 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 10 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 11 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 12 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 13 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 14 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 15 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 16 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 17 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 18 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 19 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 20 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 21 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 22 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 26 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 27 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 28 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 30 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 40 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 42 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 44 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 47 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 57 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 73 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 74 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 75 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Brooklyn ImmunoTherapeutics appears likely to maintain its strong income statement metrics, especially Return Factors. In this filing, Brooklyn ImmunoTherapeutics reported a return on equity (ROE) ratio of -1186.7, which represents a change of -443.3%. Its return factor metrics are even more remarkable when compared to their peers. Consequently, their return factors received a grade of 92. That said, one metric, EBITDA, stood out as strongly negative. Brooklyn ImmunoTherapeutics's EBIDTA now sits at -20.4 and represents -22.0% change from the last reporting period. This metric might have a 24.2 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Its EBITDA movement, therefore, received a grade of 49. their income statement received an overall score of 61.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -20.4 | -22.0% | 49 |
| Return on Equity | -1,186.7 | -443.3% | 92 |
The below chart describes Brooklyn ImmunoTherapeutics's performance as reflected on its income statement with respect to its peers. While Brooklyn ImmunoTherapeutics received a income statement score of 61 , the average of its peers stands on 57.0.
- BTX
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 0 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 2 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 5 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 10 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 11 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 12 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 13 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 14 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 15 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 16 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 17 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 18 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 19 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 20 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 21 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 22 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 26 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 27 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 28 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 30 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 40 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 42 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 47 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 73 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 74 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Brooklyn ImmunoTherapeutics's most recent cash flow report was not encouraging. Brooklyn ImmunoTherapeutics's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Brooklyn ImmunoTherapeutics recorded CapEx of -0.0, which represents a -53.5% change from the previous report. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Its CapEx movement, therefore, received a grade of 43. Also, Brooklyn ImmunoTherapeutics's management was not successful in meaningfully improving their cash flow metrics. As of the current filing, they were reported as 21.3 and represented a -52.6% change from the previous period. Brooklyn ImmunoTherapeutics's net cash flow metrics are especially disappointing relative to their peers. Hence, their net cash flow earned a score of 58. On the other hand, Free Cash flow, jumped out as looking rather positive. Brooklyn ImmunoTherapeutics did a great job related to free cash flow this period, which stood at -0.5, representing a 2.4% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 4.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. Therefore, its free cash flow movement earned a score of 72. Therefore, it received a cautionary score of 58.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 21.3 | -52.6% | 58 |
| Capital Expenditure | -0.0 | -53.5% | 43 |
| Free Cashflow | -0.5 | 2.4% | 72 |
The below chart describes Brooklyn ImmunoTherapeutics's performance as reflected on its cash flow with respect to its peers. While Brooklyn ImmunoTherapeutics received a cash flow score of 58, the average of its peers stands on 53.0.
- BTX
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 0 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 1 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 2 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 3 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 4 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 5 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 6 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 7 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 8 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 9 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 10 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 11 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 12 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 13 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 14 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 15 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 16 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 17 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 18 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 19 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 20 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 21 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 22 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 26 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 27 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 28 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 30 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 40 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 42 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 47 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 73 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 74 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.